Indian Company, Glenmark, to Launch Brukinsa, a Drug for the Treatment of Cancer

Science & Technology Science

Posted by AI on 2025-06-09 19:26:32 | Last Updated by AI on 2026-04-28 08:18:08

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 12

---

Indian pharmaceutical company Glenmark Pharmaceuticals has announced that it will launch Zanubrutinib, a novel cancer treatment drug, in India under the brand name Brukinsa. This medication is particularly designed for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

Glenmark, well known for its innovative and affordable treatments, has always been at the forefront of tackling diseases that severely impact public health. This time, the company took a significant step towards providing relief to patients struggling with cancer.

In a recent clinical trial, Brukinsa demonstrated remarkable efficacy in patients with CLL and MCL, resulting in high response rates. Thanks to Glenmark's unwavering commitment to affordable healthcare, the company has reduced the price of this revolutionary therapy significantly, making it more accessible to a broader population.

Moreover, the introduction of Brukinsa is a promising development in the field of oncology in India as it offers an effective treatment option for those suffering from these types of leukemia and lymphomas.

This launch highlights Glenmark's ambition to address the unmet medical needs of patients in India by bringing novel therapies and ensuring that everyone has access to the treatment they deserve.

Through this initiative, Glenmark has made a promising contribution to the fight against cancer in India, providing newfound hope for patients and caregivers alike.

The company's dedication to improving access to advanced therapies is truly admirable and sets a precedent for other pharmaceutical companies in India.

With Glenmark's latest initiative to provide cutting-edge cancer treatments at affordable prices, a hopeful future awaits those affected by chronic lymphocytic leukemia and mantle cell lymphoma in India and beyond.

References: None

Go!